Myocardial protection during ischemia by prior feeding with the creatine analog: Cyclocreatine  by Jacobstein, Mark D. et al.
246
Myocardial Protection During Ischemia by Prior Feeding With the
Creatine Analog   Cyclocreatine
MARK D. JACOBSTEIN, MD, FACC, THOMAS A. GERKEN, PHD, ABDUL M. BHAT, MD,
PIERRE G . CARLIER, MD, PHD
Cleveland, Ohio
The ability of 1-carboxymethyl-2-iminoimidazolidine (cy-
clocreatine), a synthetic creatine analog, to protect myocar-
dium during global ischemia was assessed in isovolumic rat
hearts using phosphorus-31 nuclear magnetic resonance
spectroscopy . Wistar rats were fed a 1 % cyclocreatine diet .
After 2 weeks, cyclocreatine-fed (n = 8) and control (n = 7)
rats were anesthetized, the heart was excised and retro-
grade perfusion was begun at 10 ml/min per g with 37°C,
phosphate-free buffer containing glucose and oxygen . He-
modynamic and spectroscopic data were obtained during
baseline, ischemia and recovery periods (each 24 min) .
During ischemia, the heart of control rats developed a
rigor-like increase in tonic pressure (ischemic contracture)
not seen in the heart of cyclocreatine-fed rats (22 versus 1
Despite the widespread use of cardioplegic solutions and
deep hypothermia during cardiac surgery, protracted ven-
tricular dysfunction continues to be an occasional but seri-
ous sequela of prolonged ischemic arrest . This is frequently
manifested as poor ventricular compliance, a form of isch-
emic contracture of the myocardium that resembles rigor in
skeletal muscles (1-3) . Prolonged cardiac failure also occurs
after unplanned ischemia despite adequate and prompt
reperfusion . The impairment of myocardial function that is
seen after ischemia can be correlated with intracellular levels
of adenosine triphosphate (ATP) (4-12) . The high energy
phosphate bond of ATP is the immediate source of energy
for myocardial contraction and relaxation . Although it is
controversial whether myocardial preservation depends on
maintenance of ATP, the close correlation between ATP
content at the end of ischemia and subsequent recovery of
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mm Hg, p < 0.01). This change was associated with
significantly more adenosine triphosphate (ATP) at end-
ischemia in the cyclocreatine group (1 .6 versus 0 .6 µmol/g,
p < 0.01) and delayed development of acidosis (p < 0 .001) .
With reperfusion, the heart of cyclocreatine-fed rats spon-
taneously defibrillated sooner than did the heart in control
rats (178 versus 346 s, p < 0 .03) . Diastolic pressure
remained significantly elevated throughout recovery in con-
trol hearts compared with treated hearts (p < 0 .001) .
Prior feeding with cyclocreatine preserves myocardial
adenosine triphosphate during ischemia, delays the devel-
opment of acidosis and ischemic contracture and improves
recovery of mechanical function on reperfusion.
(.1 Am Coll Cardiol 1 8 ;14 246-51)
myocardial function during reperfusion has been well docu-
mented (4-12) .
Several synthetic creatine analogs are available that,
when fed to animals, will accumulate in the phosphorylated
form in muscle, including myocardium (13-16) . One analog,
1-carboxymethyl-2-iminoimidazolidine (cyclocreatine), has
been shown to preserve cellular ATP and delay the onset of
rigor in isolated, excised skeletal and cardiac muscle (13-15) .
Although the mechanism for the action of cyclocreatine is
unknown, these findings suggest that cyclocreatine may
have a potential role in myocardial protection during planned
and possibly unplanned myocardial ischernia . The purpose
of this study was to investigate the effect of prior feeding
with cyclocreatine on functioning hearts during and after
global ischemia with use of phosphorus-31 nuclear magnetic
resonance spectroscopy to monitor high energy phosphates
serially and noninvasively .
Methods
Cyclocreatine feeding (treatment groups) . Cyclocreatine
was synthesized according to published methods (15) . Pow-
dered cyclocreatine was mixed with finely ground standard
laboratory rat chow in a proportion of 1 g/100 g of chow (1%
0735-10 7/8 /$3 .50
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cyclocreatine) and then repelletized . Male Wistar rats (600 to
700 g) were allowed free access to either cyclocreatine chow
(n = 10) or control chow (n = 10) for a 2 week period . Five
of the 20 hearts were inadvertently damaged during the
isolated heart preparation and were nonviable . The remain-
ing 15 hearts (cyclocreatine group [n = 8] and control group
[n = 7]) were studied to completion .
Isolated heart preparation . Rats were injected with hep-
arin (200 IU) and anesthetized with intraperitoneal pentobar-
bital (25 mg) . The heart was rapidly excised, placed in iced
cardioplegic solution, trimmed and weighed . The composi-
tion of the cardioplegic solution was sodium chloride 67 .5
mM, sodium bicarbonate 24 .0 mM, potassium chloride 34 .2
mM, and glucose  8 .0 mM. The aorta was cannulated and
retrograde perfusion begun using a constant flow of 10 ml/g
heart weight per min . Perfusate composition was sodium
chloride 142 mM, potassium chloride 5 .  mM, calcium
chloride 3 .0 mM. magnesium sulfate 1 .2 mM, ethylenedi-
aminetetraacetic acid (EDTA) 0 .5 mM, N-2-hydroxyeth-
ylpiperazine-N'-2-ethane sulfonic acid (HEPES) 6 .2 mM and
glucose 8.5 mM . The perfusate was prefiltered, adjusted to a
pH of 7 .4 with sodium hydroxide, heated to 37°C and
continuously bubbled with 100% oxygen . Perfusate temper-
ature was maintained with a thermostat-regulated circulating
water bath that surrounded the perfusion column . A second
filter (0 .45 µm) was placed in the inflow line to prevent
particulate matter from entering the coronary circuit .
The posterior atrial walls were opened and the atrioven-
tricular node crushed . The left ventricle was vented and the
right ventricular outflow tract incised to prevent fluid accu-
mulation. A fully deflated latex balloon was inserted through
the mitral orifice into the vented left ventricle and inflated
with 200 mM aqueous aminomethylphosphonate reference
solution to an initial end-diastolic pressure of 10 mm Hg .
This balloon volume was then maintained throughout the
experiment. The latex balloon was connected to a Statham
P50 transducer by a length of PE-50 tubing . A second
transducer was connected to a catheter located in the inflow
line, just above the aortic cannula tip, for determination of
perfusion pressure. Platinum-tipped graphite electrodes
were placed on the right ventricular myocardium and the
heart was paced at 4 Hz with a Grass S48 stimulator . Stimuli
consisted of 5 ms pulses at voltages slightly above threshold .
Aortic pressure and left ventricular systolic and diastolic
pressures were monitored continuously on a Gould four
channel ink-pen recorder .
The heart was carefully placed in a 20 mm glass tube so as
to avoid significant contact of the left ventricle with the walls
of the tube . Effluent perfusate was evacuated from the tube
at a level above the heart so that the preparation was fully
immersed. Perfusate solution was not recycled .
Nuclear magnetic resonance spectroscopy . The heart
preparation was positioned within the probe of a supercon-
ducting magnet (Brucker WH 180, 4 .2 T, phosphorus reso-
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nance frequency 72.8  MHz) interfaced with a Nicolet 1180
computer. Magnetic field homogeneity and lock were main-
tained by the proton resonance of water in the perfusate .
Free induction decays were obtained with a pulse duration of
20 µs (40° flip angle) and a pulse repetition rate of I s . Free
induction decays were accumulated for 3 min (180 scans)
with a 2K data table at 8 kHz spectral width, stored on hard
disk and Fourier transformed after a 20 Hz line broadening
exponential multiplication . To correct for partial saturation,
a fully relaxed spectrum was acquired during the baseline
period ( 0° flip angle, pulse interval of 8 s,  2 scans, 12 min
acquisition time) and correction factors were determined .
Saturation factors were determined for each phosphate
moiety and the mean value for each group of hearts was used
to correct for insufficient relaxation .
Experimental protocol . The experimental protocol con-
sisted of 1) a 24 min baseline period during which four 3 min,
short-delay spectra and one 12 min fully-relaxed spectrum
were collected   2) a 24 min global ischemia period during
which perfusion and pacing were discontinued ; and 3) a 24
min recovery period during which perfusion and pacing were
resumed . During both ischemia and reperfusion, hemody-
namic measurements and consecutive short-delay spectra
were obtained every 3 min .
Chemical assay of creatine and cyclocreatine . After the
perfusion protocol, hearts were frozen, lyophilized and
subsequently assayed for cyclocreatine and creatine by
colorimetric methods . Creatine was assayed at 525 nm
by the diacetyl-a-naphthol method (17) and cyclocreatine
at 605 nm by the sodium-pentacyanoamine ferroate
(Na 3[Fe(CN) SNH3 ]) method (15) using a Varian DMS- 0
spectrophotometer . Data are expressed as micromoles per
gram of dry weight .
Data analysis and statistics . Mechanical performance of
the heart was assessed by measuring left ventricular devel-
oped pressure (peak minus rest) and left ventricular end-
diastolic pressure. The characteristic peaks for inorganic
phosphate, phosphagen, beta-adenosine triphosphate and
the aminomethylphosphonate reference were identified and
the area under each peak was determined by computer
planimetry . Myocardial concentrations of inorganic phos-
phate, phosphagen and ATP were measured by computing
(cardiac compound peak area x reference amount)/(refer-
ence peak area x heart wet weight) expressed as micromoles
per gram of wet heart weight . Intracellular pH was deter-
mined from the chemical shift of inorganic phosphate rela-
tive to the reference by extrapolation to a previously deter-
mined pH titration curve .
Two-way analysis of variance (ANOVA) for repeated
measures was performed where appropriate using one fixed
or group factor (diet) and one repeated measures factor
(time) . One-way ANOVA was used to compare body weight,
heart weight and heart/body weight ratio ; gain in diastolic
pressure during ischemia ; time to spontaneous defibrillation ;
baseline values of mechanical performance and myocardial
phosphates and creatine/cyclocreatine content between the
two groups . The rate of decline of ATP during ischemia was
compared between groups by testing for parallelism of slope .
All data are presented as mean values ± 1 SE . This work
conforms to the position of the American Heart Association
on research animal use .
Results
Heart weight, body weight and heart/body weight ratio
were not significantly different between the two groups
(Table 1) .
Mechanical Performance (Fig . 1)
Baseline period . Perfusion pressure (aortic pressure mi-
nus left ventricular end-diastolic pressure) was not signifi-
cantly different between the two groups (cyclocreatine 4 
4 mm Hg, control 53 ± 3 mm Hg) . Hearts in the cyclocre-
atine group had a slightly greater baseline developed pres-
sure (82 ± 3 versus 71 ± 4 mm Hg, p < 0 .05). Diastolic
pressure (Fig . 1) was not different between groups during the
preischemic, baseline period .
Ischemia . Within seconds of the onset of ischemia, all
hearts developed asystole with a low tonic or static pressure
equal to diastolic pressure . Tonic pressure, which remained
low in cyclocreatine-fed rat hearts throughout ischemia,
began to increase in control hearts after 15 min of no flow
(Fig. 1). By end-ischemia, tonic pressure was markedly
elevated in control hearts (2  ± 6 versus 8 ± 2 mm Hg) .
During the ischemic period, therefore, tonic pressure in-
creased by only 1 ± 1 mm Hg in treated hearts compared
with 22 ± 7 mm Hg in control hearts (p = 0 .005) .
Recovery . All the hearts in cyclocreatine-fed rats spon-
taneously defibrillated within 4 min of the onset of reperfu-
sion (mean 178 ± 8 s) . Control hearts demonstrated delayed
recovery compared with the cyclocreatine group ; no control
heart developed paced rhythm in the first 4 min and the mean
time of onset of spontaneous defibrillation was twice that of
the treated hearts (346 ± 77 s, p < 0 .025) .
By the end of the recovery period all eight hearts in the
cyclocreatine group had returned to preischemic levels of
developed pressure as had five of the seven control hearts .
Diastolic pressure transiently increased during reperfusion
24 1 3 6   12 15 18 2124, 3 6   12 15 18 21 24 ,
B
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Figure 1 . Left ventricular end-diastolic pressure during baseline
(B), ischemia and recovery periods . Diastolic pressure increased
markedly after 15 min of ischemia in the heart of control rats and
remained persistently elevated throughout reperfusion whereas the
heart of cyclocreatine-fed (cyclo) rats maintained low, baseline
pressure during ischemia and reperfusion . The effect of the cy-
clocreatine diet on diastolic pressure was highly significant (p <
0.001) .
in the cyclocreatine group, then rapidly decreased to pre-
ischemic levels and remained low throughout the rest of
recovery . In contrast, the elevated diastolic pressure seen in
control hearts at end-ischemia persisted throughout recov-
ery (Fig. 1). The time course of diastolic pressure was
significantly different between groups (p < 0 .001) .
Myocardial Phosphates (Fig . 2 to 4)
Typical spectra are shown in Figure 2 . It was not pos-
sible to separate phosphocreatine from cyclocreatine phos-
phate in the perfused heart because of the broadening
of peaks that occur in spectroscopy of whole organs . There-
fore, only total high energy phosphagens (phosphocreatine
or cyclocreatine phosphate, or both) could be measured
and quantified .
Phosphagens . Baseline total phosphagen levels were not
significantly different between groups (cyclocreatine 8 .4
0.7 emol/g, control 8 .5 ± 1 .0 µmol/g) . During ischemia,
however, there was a rapid decrease in high energy phos-
phagens (Fig. 2 and 3A) that was greater in control hearts ; at
the end of ischemia there was 1 .0 ± 0.3 Amol/g of phos-
phagen (11 ± 3% of the preischemic level) in treated hearts
versus 0.2 ± 0.2 Amol/g (2 ± 3% of baseline) in control
hearts (p < 0 .05) . During reperfusion, phosphagens were
rapidly repleted to levels that exceeded the preischemic
baseline values in both groups, with control hearts exhibiting
a greater overshoot (Fig . 3A). The time course of myocardial
phosphagens during the protocol was significantly different
between groups (p < 0 .001) .
Adenosine triphosphate (ATP) . Baseline levels of ATP
were not significantly different between groups (cyclocre-
atine 3.  ± 0.5 µmol/g, control 4 .  ± 0.5 µmol/g). Adenosine
triphosphate levels decreased during ischemia but, unlike
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Table 1 . Body Weight, Heart Weight and Heart/Body Weight 40
Ratio (mean ± SE)
30
• Cyclo
∎ Control
Cyclocreatine Control
If-P < .001
Group (n = 8) Group (n = 7) p Value
E 20
650 ± 20
682 ± 10
Body weight (g)
NS
E
Heart weight (g) 2 .3 ± 0 .1 2 .1 ± 0 .1 NS
Heart/body weight (mg/g) 3 .6 ± 0 .1 3 .3 ± 0 .2 NS
10
44444-1
0
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Figure 2 . Representative phosphorus-31 nuclear mag-
netic resonance spectra from a control heart
(A) and the
heart of a rat fed cyclocreatine (B) during the baseline
period (upper) and after 6 (middle) and 24 (lower) min of
ischemia. During ischemia, inorganic phosphate (P ;)
increased rapidly in both hearts but the increase was
less in the cyclocreatine heart . Phosphagens (Phos)
decreased in both hearts but at a much slower rate in the
cyclocreatine heart ; the phosphagen peak was almost
completely gone after 6 min of ischemia in the control
heart whereas significant phosphagen was still present in
the cyclocreatine heart . Adenosine triphosphate (ATP)
was relatively preserved in the cyclocreatine heart even
after 24 min of ischemia . PPM = parts per million ;
Ref = aminomethylphosphonate reference .
A
Ref
1
phosphagens, ATP recovery was incomplete (Fig . 2 and 3B) .
Adenosine triphosphate was relatively spared during isch-
emia in the cyclocreatine group . At the end of the ischemic
period there was 1 .6 ± 0 .2 amol/g of ATP in the hearts of the
cyclocreatine group (45 ± 7% of preischemic levels) versus
0.6 ± 0.2 µmol/g (14 ± 5% of baseline) in control hearts (p <
0.005) . The decline in ATP levels during ischemia was linear
in both groups, but occurred at a significantly slower rate in
the cyclocreatine group (-0 .0  ± 0.01 versus -0 .18 ± 0.01
µmol/g per min, p < 0 .0001 for parallelism of slope) (Fig .
3B). During ischemia, therefore, ATP decreased twice as
fast in the control hearts as it did in the treated hearts . The
overall time course of myocardial ATP during the protocol
was significantly different between groups (p < 0 .001) .
Inorganic phosphate . Inorganic phosphate was present in
only minute quantities during the baseline period but in-
creased rapidly during ischemia in both groups (Fig . 2 and
3C) . However, the rate and extent of increase in inorganic
phosphate during ischemia were greater in control hearts
(p < 0.001) .
Intracellular pH (Fig. 4). The rate of development of
acidosis during ischemia was significantly less in the cy-
clocreatine group than in the control group (p < 0 .001) .
Chemical assay of creatine and cyclocreatine . Total cre-
atine content was not significantly different between groups  
45.3 ± 1 .3 versus 4  .6 ± 2 .2 imol/g dry weight. Hearts in the
cyclocreatine group, however, had 31 .6 ± 1 .7 Amol/g of
cyclocreatine so that total myocardial creatine/cyclocreatine
content was increased (76 .  ± 2 .6 versus 4  .6 ± 2 .2 µmol/g,
p < 0.001) .
Phos
Y
ATP
0
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Discussion
Protective effect of cyclocreatine during ischemia . Prior
feeding with cyclocreatine, a synthetic creatine analog, has
been shown to delay the onset of rigor and preserve levels of
ATP in isolated excised rat, chick and mouse skeletal muscle
and in rat and chick myocardium . These studies (13-15),
however, did not evaluate functioning hearts and, therefore,
could not assess the effect of cyclocreatine on cardiac
function and could not assess reperfusion . The current study
demonstrates, in a functioning heart model, that cyclocre-
atine significantly protects myocardium from ischemia and
results in improved postischemic recovery .
Hearts from the cyclocreatine group demonstrated a
slower rate and magnitude of decline of high energy phos-
phagens and ATP, decreased production of inorganic phos-
phate and a slower rate of development of intracellular
acidosis during ischemia than did control hearts . The most
striking effect of cyclocreatine was on ATP metabolism
during ischemia; ATP levels declined in the cyclocreatine
group at half the rate of decline in control hearts . As a result,
no treated heart developed ischemic contracture, a phenom-
enon that occurs when the ATP concentration falls below
that necessary to maintain relaxation, thus fixing the myosin
cross-bridges to actin (3,18-20) . Control hearts, on the other
hand, began to develop ischemic contracture at 15 min of
ischemia concomitant with the decrease in ATP levels below
2 Amol/g . Adenosine triphosphate levels declined further in
control hearts as contracture progressed and reached a nadir
of < 1 µmol/g at the peak of ischemic contracture . These
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Figure 3. Myocardial phosphates during baseline (B), ischemia and
recovery periods . Values shown are micromoles per gram of wet
heart weight . A, Phosphagens declined rapidly during ischemia in
both the control and treated groups and recovered rapidly and
completely during reperfusion . However, the decrease in phos-
phagens during ischemia was less in the heart of rats fed cyclocre-
atine (cyclo). The time course for phosphagens was significantly
different between groups (p < 0 .001) . B, During ischemia, adenosine
triphosphate (ATP) decreased at a significantly slower rate in
cyclocreatine-fed group (p < 0 .0001 for differences in slope) . The
overall time course of ATP was significantly different between
groups (p < 0 .001) . C, Inorganic phosphate increased rapidly during
ischemia and rapidly returned to baseline levels during reperfusion .
Hearts in the cyclocreatine group accumulated significantly less
inorganic phosphate during ischemia than did the control hearts .
The intergroup differences in inorganic phosphate during the proto-
col were significant (p < 0 .001) .
findings are in excellent agreement with the data of Hearse et
al . (3), who demonstrated that contracture begins when
cellular ATP content decreases to 12 µmol/g dry weight
(approximately 2 umol/g wet weight), progresses rapidly as
ATP degradation accelerates and reaches a peak when ATP
is at levels of 3 to 4 µmol/g dry weight (< I µmol/g wet
weight) .
During reperfusion, phosphagens were rapidly repleted to
normal or above normal levels in both groups, indicating that
pH
7.0
6. 
6.8
6.7
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Figure 4 . Time course of intracellular pH (pH i ) determined from
the chemical shift of inorganic phosphate relative to the reference
during ischemia . The rate at which acidosis developed during
ischemia was less in hearts in the cyclocreatine (cyclo) group (p <
0.001) .
the mitochondrial mechanisms responsible for oxidative
phosphorylation were intact . Adenosine triphosphate, how-
ever, was incompletely replenished, presumably because of
the loss of diffusible adenine precursors during reperfusion
(7,21-24) . Mechanical function recovered more readily in
hearts in the cyclocreatine group as demonstrated by a faster
return of paced rhythm and return to normal of diastolic
pressure. This study confirms the findings of others (4-12)
that recovery of mechanical function after ischemia corre-
lates well with the ATP level at end-ischemia because hearts
in the cyclocreatine group had significantly more ATP at
end-ischemia than did control hearts .
Mechanism of action of cyclocreatine . The mechanism by
which cyclocreatine feeding spares myocardial ATP levels
during ischemia is unknown . One possibility is that prior
cyclocreatine feeding results in the accumulation of an
increased pool of high energy phosphagens in the heart (in
the form of cyclocreatine phosphate) that are available for
use during ischemia (13) . Our data, however, suggest that
total high energy phosphagens were not increased before
ischemia .
Another possible explanation for the protective effect of
cyclocreatine is increased glycolysis, because cyclocreatine-
fed animals have been shown to have increased cardiac
glycogen stores (13) . However, if increased anaerobic me-
tabolism were present, one would expect an increased rate
of acid production. In fact, acidosis was delayed in the
cyclocreatine group, which suggests that the rate of glycol-
ysis was, if anything, slowed . This is in agreement with the
data of Roberts and Walker (13), who demonstrated similar
rates of glycolysis (lactate production) in cyclocreatine and
control hearts through the first 60 min of ischemia .
Sparing of ATP during ischemia . At the onset of isch-
emia, total moles of high energy phosphates (ATP + phos-
phagens) per gram of myocardium were equal in the two
groups. However, by the end of ischemia, high energy
phosphates in the cyclocreatine group exceeded that found
in control hearts . Because aerobic metabolism is eliminated
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during ischemia and anaerobic metabolism is not signifi-
cantly different between the two groups, the only other
explanation for sparing of ATP during ischemia is some
direct or indirect depressive effect of cyclocreatine on myo-
cardial metabolism (ATP utilization) . This possibility is
supported by the slower increase in inorganic phosphate
seen in the heart of cyclocreatine-fed rats during ischemia .
Cyclocreatine or cyclocreatine phosphate may modulate the
rate or extent of ATP utilization during ischemia in some as
yet unknown fashion either at the contractile protein level or
at the membrane level .
Conclusions . This study demonstrates that prior feeding
of the creatine analog cyclocreatine preserves myocardial
ATP during ischemia, delays the development of ischemic
contracture and intracellular acidosis and improves recovery
of mechanical function during reperfusion . Although the
mechanism is not entirely known, it would appear that
cyclocreatine (or cyclocreatine phosphate) acts directly or
indirectly to reduce ATP utilization and augment pH buff-
ering during ischemia. Whether cyclocreatine would be
useful in vivo during planned (cardioplegic) or unplanned
ischemia remains to be proved .
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